High performance liquid chromatography method for impurities in dexketoprofen trometamol

A high-performance liquid chromatography method using octadecylsilane bonded silica and a gradient elution with phosphate-acetonitrile solution effectively separates and quantifies impurities in dexketoprofen tromethamine, addressing the inadequacies of existing methods and ensuring high accuracy and specificity in impurity detection.

CN119086764AInactive Publication Date: 2024-12-06GUANGDONG ZHONGRUN DRUG RES & DEV CO LTD

Patent Information

Application Number
CN202411285446.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-13
Publication Date
2024-12-06
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current pharmacopoeia methods are inadequate for detecting impurities in dexketoprofen tromethamine injection, particularly under strong light conditions, leading to poor peak shape and separation, and existing methods fail to address these challenges, and existing methods are not suitable for the analysis of related substances in this drug.

Method used

A high-performance liquid chromatography analysis method is developed, utilizing octadecylsilane bonded silica as a filler and a specific chromatography analysis method is developed, utilizing phosphate-acetonitrile solution as a mobile phase A and acetonitrile as mobile phase B, with a gradient elution method to effectively separate impurities in dexketoprofen tromethamine.

Benefits of technology

The method effectively separates and quantifies impurities in dexketoprofen tromethamine, ensuring high accuracy, specificity, and no interference from auxiliary material peaks, with a short analysis time, thus improving the quality control and safety of the drug.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119086764A_ABST
    Figure CN119086764A_ABST
Patent Text Reader

Abstract

The invention discloses a high performance liquid chromatography analysis method of a dexketoprofen trometamol related substance, which comprises the following steps: taking a dexketoprofen trometamol sample to be detected, preparing a test solution, injecting the test solution into a high performance liquid chromatograph, and detecting and recording a chromatogram under the following chromatographic conditions, a phosphate-acetonitrile solution is used as a mobile phase A; acetonitrile is used as a mobile phase B; the elution mode is gradient elution. By adopting the method disclosed by the invention, related substances in the dexketoprofen trometamol sample to be detected can be effectively separated and determined; and the used detection method has the advantages of strong separation capacity, simple operation process, strong specificity, no interference of auxiliary material peaks on detection and short analysis time. By utilizing the method disclosed by the invention, qualitative and quantitative analysis of the dexketoprofen trometamol preparation can be quickly and accurately carried out, the liquid phase analysis accuracy is high, the repeatability is good, and the quality control of the product production process can be more effectively realized.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of drug detection, and particularly relates to a high performance liquid chromatography analysis method for impurities in dexketoprofen tromethamine. Background Art

[0002] Dexketoprofen tromethamine is a nonsteroidal anti-inflammatory drug. Its mechanism of action is to inhibit the synthesis of prostaglandins to exert anti-inflammatory and analgesic effects. It is clinically suitable for the symptomatic treatment of acute moderate to severe pain when oral administration is not possible, such as postoperative pain, renal colic, low back pain, etc. The chemical name of dexketoprofen tromethamine is (+)-(S)-3'-benzoyl-2-phenylpropionic acid 2-amino-2-hydroxymethyl-1,3-propanediol salt. Its structural formula is shown in formula (I):

[0003]

[0004] Dexketoprofen tromethamine is widely used in Europe. There is sufficient clinical evidence that dexketoprofen tromethamine injection has a significant analgesic effect in the treatment of acute renal colic, postoperative pain and acute low back pain, and can reduce the use of opioids in multimodal analgesia. The oral dosage form of dexketoprofen tromethamine was first launched in Spain in 1996 and was developed by Menarini for the treatment of inflammation and pain. In 2002, the injection developed by the manufacturer was first approved for marketing in Spain. It is currently not available in the United States, Japan, and China, and is only available in EU member states.

[0005] At present, the quality standards for dexketoprofen tromethamine injection are not included in the American, European, British, Japanese and Chinese Pharmacopoeia, but the Chinese Pharmacopoeia 2020 (ChP2020) includes dexketoprofen tromethamine capsules, and the British Pharmacopoeia 2020 (BP2020) includes ketoprofen injection. Since the dexketoprofen tromethamine capsules ChP2020 quality standard does not control the relevant substance inspection items, the ketoprofen injection BP2020 quality standard stipulates the relevant substance inspection items, and the inspection method is the highly sensitive HPLC method. Therefore, the dexketoprofen tromethamine injection is intended to refer to the ketoprofen injection BP2020 quality standard for relevant substance detection, and optimize and establish the relevant substance detection method based on the relevant substance method included in it.

[0006] According to the relevant substance detection method in the BP2020 quality standard of Ketoprofen Injection, the specificity of the method was investigated using samples of strong acid, strong alkali, high temperature, oxidation and strong light (different time) degradation of dexketoprofen tromethamine injection. The results showed that the preparation of this product was relatively stable to strong acid, strong alkali and oxidation conditions, but unstable under high temperature and strong light conditions, and produced obvious degradation impurities. The purity of the main component peaks in the chromatograms of strong acid, strong alkali, oxidation and high temperature degradation samples met the requirements, and the impurities and the main peaks, and the impurities and impurity peaks did not interfere with the detection, and the separation met the requirements. However, the chromatograms of the samples degraded by strong light showed that the peak shape and separation of some impurity peaks after the main peak were poor, which needed further optimization. At present, the pharmacopoeia methods of various countries are not suitable for the detection of related substances of dexketoprofen tromethamine injection. At the same time, there are no reports of detection methods for related substances of dexketoprofen tromethamine injection at home and abroad, and no other applicable public methods have been retrieved. Therefore, it is very necessary to develop a related substance detection method suitable for dexketoprofen tromethamine injection to achieve quality control of dexketoprofen tromethamine injection. Summary of the invention

[0007] In order to overcome the problems existing in the above-mentioned prior art, the object of the present invention is to provide a high performance liquid chromatography analysis method for impurities in dexketoprofen tromethamine.

[0008] In order to achieve the above object, the technical solution adopted by the present invention is:

[0009] The invention provides a high performance liquid chromatography analysis method for impurities in dexketoprofen tromethamine, comprising the following steps: taking a dexketoprofen tromethamine sample to be tested, preparing a test solution, injecting the test solution into a high performance liquid chromatograph, and detecting and recording a chromatogram under the following chromatographic conditions: using octadecylsilane bonded silica gel as a filler; using phosphate-acetonitrile solution as a mobile phase A; using acetonitrile as a mobile phase B; and using gradient elution as an elution method;

[0010] The procedure of the gradient elution is shown in Table 1:

[0011] Table 1

[0012] Time (minutes) Mobile phase A (%) Mobile phase B (%) 0 74~77 26~23 5 74~77 26~23 20 68~71 32~29 35 34~37 66~63 50 34~37 66~63 51 74~77 26~23 60 74~77 26~23

[0013] More preferably, the procedure of the gradient elution is as shown in Table 2:

[0014] Table 2

[0015]

[0016]

[0017] Preferably, the dexketoprofen tromethamine related substances include the following impurities:

[0018] The invention can simultaneously separate process impurities of dexketoprofen tromethamine injection liquid raw materials, and can also effectively separate main degradation impurities of the injection liquid under various forced degradation and stability conditions.

[0019] More preferably, the method comprises the following steps:

[0020] 1) Preparation of test solution: Take the dexketoprofen tromethamine sample to be tested and dissolve it in the diluent to prepare the test solution;

[0021] Preparation of control solution: Take the test solution and further dilute it with diluent to obtain the control solution;

[0022] Preparation of system suitability solution: take appropriate amount of impurity A reference substance, impurity B reference substance, impurity C reference substance, impurity D reference substance, impurity E reference substance, impurity F reference substance, impurity M reference substance, impurity N reference substance, impurity O reference substance, impurity P reference substance, impurity Q reference substance and dexketoprofen tromethamine reference substance, and prepare system suitability solution with diluent;

[0023] 2) Use high performance liquid chromatography to measure the system suitability solution, control solution and test solution respectively, inject them into the chromatograph, perform gradient elution, and record the chromatogram.

[0024] Further preferably, the diluent is prepared by mixing 1 wt % phosphoric acid solution with acetonitrile, and the volume percentage of the 1 wt % phosphoric acid solution in the diluent is 40-60%.

[0025] Further preferably, the dexketoprofen tromethamine sample to be tested is dexketoprofen tromethamine injection solution. Still further preferably, the volume ratio of the dexketoprofen tromethamine injection solution to the diluent is 1:(20-30).

[0026] More preferably, the control solution is prepared with a dilution factor of 500 to 1000 times.

[0027] Further preferably, the concentrations of the impurity A reference substance, the impurity B reference substance, the impurity C reference substance, the impurity D reference substance, the impurity E reference substance, the impurity F reference substance, the impurity M reference substance, the impurity N reference substance, the impurity O reference substance, the impurity P reference substance, and the impurity Q reference substance in the system suitability solution are all 1 to 4 μg / mL.

[0028] Further preferably, the concentration of the dexketoprofen tromethamine reference substance in the system suitability solution is 0.5 to 2 mg / mL.

[0029] More preferably, the method further comprises the following steps: taking a blank auxiliary material solution of dexketoprofen tromethamine injection and diluting it with a diluent to obtain a blank auxiliary material solution.

[0030] Preferably, the chromatographic conditions further include: a column temperature of 25 to 35° C.; and a flow rate of 0.9 to 1.1 mL / min.

[0031] Preferably, the chromatographic conditions further include: the detector is an ultraviolet detector; and the detection wavelength is 231-235 nm.

[0032] Preferably, the mobile phase A is prepared by preparing a phosphate solution and acetonitrile, and the pH value of the phosphate solution is 3.4-3.6.

[0033] More preferably, the phosphate solution is adjusted to a pH value of 3.5 using a 10% phosphoric acid solution.

[0034] More preferably, the volume ratio of the phosphate solution to acetonitrile is 4:1

[0035] More preferably, the phosphate solution is selected from potassium dihydrogen phosphate aqueous solution.

[0036] More preferably, the concentration of phosphate in the phosphate-acetonitrile solution is 0.01 to 0.02 mol / L.

[0037] Preferably, the chromatographic conditions use a chromatographic column with a filler particle size of 3 μm.

[0038] Preferably, the method comprises the following steps: firstly subjecting the dexketoprofen tromethamine sample to be tested to light destruction.

[0039] The beneficial effects of the present invention are:

[0040] The invention establishes a high performance liquid chromatography analysis method for dexketoprofen tromethamine related substances. The method of the invention can effectively separate and determine the related substances in a dexketoprofen tromethamine test sample, and the detection method used has the advantages of strong separation ability, simple operation process, strong specificity, no interference of auxiliary material peaks with detection and short analysis time. The method of the invention can be used to quickly and accurately perform qualitative and quantitative analysis of dexketoprofen tromethamine related substances, the liquid phase analysis has high accuracy and good repeatability, and the quality control of dexketoprofen tromethamine injection can be achieved, the quality of the final product is improved, and the safety and effectiveness of clinical medication are guaranteed. BRIEF DESCRIPTION OF THE DRAWINGS

[0041] Figure 1 The chromatogram of the sample solution destroyed by strong light in Example 1;

[0042] Figure 2 Overlay chromatograms of samples degraded by strong light (at different times) in Comparative Example 1;

[0043] Figure 3 The chromatogram of the sample solution destroyed by strong light in Comparative Example 2;

[0044] Figure 4 The chromatogram of the sample solution destroyed by strong light in Comparative Example 3;

[0045] Figure 5 The chromatogram of the sample solution destroyed by strong light in Comparative Example 4;

[0046] Figure 6 is the system suitability solution chromatogram of Example 1;

[0047] Figure 7 It is the blank auxiliary material solution chromatogram of Example 1;

[0048] Figure 8 It is the sensitivity solution chromatogram of Example 1;

[0049] Fig. 9 This is a linear trend diagram for the related substance inspection of Example 1. DETAILED DESCRIPTION

[0050] The present invention is further described in detail below through specific examples. The raw materials used in the following examples, unless otherwise specified, can be obtained from conventional commercial sources or prepared and separated by simple synthesis; the processes used, unless otherwise specified, are conventional processes in the art.

[0051] Example 1

[0052] 1. Instruments and reagents

[0053] Instrument: Agilent 1260II high performance liquid chromatograph / Thermo Ultimate 3000 high performance liquid chromatograph, UV detector.

[0054] Reagents: Potassium dihydrogen phosphate, phosphoric acid, and acetonitrile were of chromatographic grade. The dexketoprofen tromethamine reference substance was independently calibrated by the inventor using dexketoprofen tromethamine raw materials, and the impurity reference substances were purchased by the applicant.

[0055] Diluent: 1% phosphoric acid solution-acetonitrile (50:50).

[0056] Preparation of system suitability solution: Take impurity A reference substance (CAS: 66067-44-5), impurity B reference substance (CAS: 22071-22-3), impurity C reference substance (CAS: 68432-95-1), impurity D reference substance (CAS: 10725-20-5), impurity E reference substance (CAS: 59512-16-2), impurity F reference substance (CAS: 42872-30-0), impurity M reference substance (CAS: 63444-57-5), impurity N reference substance (CAS: 66067-43 -4), impurity O reference substance (CAS: 67173-18-6), impurity P reference substance (CAS: 1777829-91-0) and impurity Q reference substance (CAS: 2716236-51-8) and dexketoprofen tromethamine reference substance (CAS: 156604-79-4), respectively, are dissolved in diluent and quantitatively diluted into a mixed solution containing approximately 2 μg of impurity A, impurity B, impurity C, impurity D, impurity E, impurity F, impurity M, impurity N, impurity O, impurity P and impurity Q per 1 mL, and 1 mg of dexketoprofen.

[0057] Preparation of test solution: Accurately measure 2 mL of dexketoprofen tromethamine injection, place it in a 50 mL volumetric flask, dilute to the scale with diluent, shake well, and obtain.

[0058] Preparation of control solution: Accurately measure 1 mL of the test solution, place it in a 50 mL volumetric flask, dilute it to the mark with diluent, shake well, accurately measure 2 mL, place it in a 20 mL volumetric flask, dilute it to the mark with diluent, shake well, and you have the solution (containing approximately 2 μg / mL of dexketoprofen).

[0059] Preparation of blank excipient solution: Take about 1.8 mL of water for injection, add 200 mg of ethanol (96%) and 8 mg of sodium chloride (for injection) in sequence, stir to dissolve, adjust the pH to 7.4 with 2 mol / L sodium hydroxide solution, make up to 2 mL with water for injection, and prepare the blank excipient solution of dexketoprofen tromethamine injection; accurately measure 1 mL of the blank excipient solution of dexketoprofen tromethamine injection, place it in a 25 mL volumetric flask, dilute to the scale with diluent, shake well, and obtain.

[0060] Preparation of sensitivity solution: Accurately measure 5 mL of control solution, place it in a 20 mL volumetric flask, dilute to the scale with diluent, shake well, and use it as the sensitivity solution.

[0061] Preparation of mixed impurity stock solution for spiked use: Weigh 5 mg each of impurity A, impurity B, impurity C, impurity D, impurity E, impurity F, impurity M, impurity N, impurity O, impurity P and impurity Q, accurately weigh, place in the same 50 mL volumetric flask, add appropriate amount of diluent to dissolve and dilute to the scale, shake well, and use as the mixed impurity stock solution.

[0062] Preparation of the test sample spiked solution: Accurately measure 2 mL of dexketoprofen tromethamine injection and place it in a 50 mL volumetric flask. Accurately add 1 mL of mixed impurity stock solution for spiked solution, dilute to the scale with diluent, shake well, and obtain.

[0063] 2. Liquid chromatography conditions

[0064] Detector: UV detector;

[0065] Chromatographic column: chromatographic column with octadecylsilane bonded silica as filler (Ultimate XB-C18 150mm×4.6mm, 3μm or chromatographic column with equivalent separation performance);

[0066] Mobile phase: Mobile phase A: 0.015 mol / L potassium dihydrogen phosphate solution (adjust pH to 3.5 with 10% phosphoric acid solution)-acetonitrile (80:20); Mobile phase B: acetonitrile;

[0067] The gradient elution program is shown in Table 3:

[0068] Table 3

[0069] Time (minutes) Mobile phase A (%) Mobile phase B (%) 0 75 25 5 75 25 20 70 30 35 35 65 50 35 65 51 75 25 60 75 25

[0070] Flow rate: 1.0 mL / min;

[0071] Column temperature: 30°C;

[0072] Detection wavelength: 233nm;

[0073] Injection volume: 15 μL.

[0074] 3. Take one vial of dexketoprofen tromethamine injection and place it in a light box (5500Lux±500Lux) for 3 hours. Take it out and accurately measure 2mL and place it in a 50mL volumetric bottle. Dilute it to the mark with diluent and shake well to obtain the light-damaged test solution. Inject the sample and record the chromatogram. The result is as follows: Figure 1 And as shown in Table 4.

[0075] Table 4 HPLC results

[0076]

[0077]

[0078] By Figure 1 From the results in Table 4, it can be seen that under the chromatographic conditions, the chromatographic condition specificity meets the requirements for the detection of related substances of this product.

[0079] Comparative Example 1

[0080] 1. The instruments and reagents are the same as those in Example 1.

[0081] 2. Liquid chromatography conditions

[0082] Detector: UV detector;

[0083] Chromatographic column: chromatographic column with octadecylsilane bonded silica as filler (Ultimate XB-C18 150mm×4.6mm, 3μm or chromatographic column with equivalent separation performance);

[0084] Mobile phase: pH 3.5 phosphate buffer (68 g of potassium dihydrogen phosphate was weighed and dissolved in 1000 mL of water, and the pH value was adjusted to 3.5 with 10% phosphoric acid solution)-acetonitrile-water (2:43:55);

[0085] Isocratic elution was used;

[0086] Flow rate: 1.0 mL / min;

[0087] Column temperature: 30°C;

[0088] Detection wavelength: 233nm;

[0089] Injection volume: 20 μL.

[0090] 3. Take 4 vials of dexketoprofen tromethamine injection and place them in a light box (5500Lux±500Lux). Take them out at 10min, 30min, 1h, and 3h respectively. Accurately measure 2mL each and place them in different 50mL volumetric bottles. Dilute to the mark with diluent and shake well to obtain the test sample solutions destroyed by light at different times. Inject the sample and record the chromatogram. The results are as follows: Figure 2 .

[0091] The specificity of the method was investigated by degrading dexketoprofen tromethamine samples under strong light (for different time periods). The results showed that the preparation was unstable under strong light conditions and produced obvious degradation impurities. The chromatogram of the sample degraded under strong light showed that the peak shape and separation of some impurity peaks after the main peak were poor, which needed further optimization.

[0092] Comparative Example 2

[0093] 1. The instruments and reagents are the same as those in Example 1.

[0094] 2. Liquid chromatography conditions

[0095] Detector: UV detector;

[0096] Chromatographic column: chromatographic column with octadecylsilane bonded silica as filler (Ultimate XB-C18 150mm×4.6mm, 3μm or chromatographic column with equivalent separation performance);

[0097] Mobile phase: Mobile phase A: pH 3.5 phosphate buffer-acetonitrile-water (2:20:78); Mobile phase B: acetonitrile;

[0098] The gradient elution program is shown in Table 5:

[0099] Table 5

[0100] Time (minutes) Mobile phase A (%) Mobile phase B (%) 0 100 0 5 100 0 25 65 35 45 20 80 46 100 0 55 100 0

[0101] Flow rate: 1.0 mL / min;

[0102] Column temperature: 30°C;

[0103] Detection wavelength: 233nm;

[0104] Injection volume: 20 μL.

[0105] 3. Take 5 mL of dexketoprofen tromethamine injection, place it in a 20 mL headspace bottle, roll on the cap and seal it, place it in a light box (5500 Lux ± 500 Lux) for 3 hours, take it out, and use it as light-damaged sample 1. Take 1 bottle of dexketoprofen tromethamine injection, place it in a light box (5500 Lux ± 500 Lux) for 7 hours, take it out, and use it as light-damaged sample 2. Accurately measure 1 mL each of light-damaged sample 1 and light-damaged sample 2, place them in the same 50 mL volumetric bottle, dilute to the scale with diluent, shake well, and you will get the light-damaged test solution. Inject the sample, record the chromatogram, and the results are as follows: Figure 3 And as shown in Table 6.

[0106] Table 6 HPLC results

[0107]

[0108]

[0109] The specificity of the method was investigated using samples of this product degraded under strong light. The results showed that the main peak and impurity peaks overlapped and the gradient was not applicable.

[0110] Comparative Example 3

[0111] 1. The instruments and reagents are the same as those in Example 1.

[0112] 2. Liquid chromatography conditions

[0113] Detector: UV detector;

[0114] Chromatographic column: chromatographic column with octadecylsilane bonded silica as filler (Ultimate XB-C18 150mm×4.6mm, 3μm or chromatographic column with equivalent separation performance);

[0115] Mobile phase: Mobile phase A: pH 3.5 phosphate buffer-acetonitrile-water (2:20:78); Mobile phase B: acetonitrile;

[0116] The gradient elution program is shown in Table 7:

[0117] Table 7

[0118]

[0119]

[0120] Flow rate: 1.0 mL / min;

[0121] Column temperature: 30°C;

[0122] Detection wavelength: 233nm;

[0123] Injection volume: 20 μL.

[0124] 3. Take one vial of dexketoprofen tromethamine injection and place it in a light box (5500Lux±500Lux) for 7 hours. Take it out and accurately measure 2mL and place it in a 50mL volumetric bottle. Dilute it to the mark with diluent and shake well to obtain the light-destroyed test solution. Inject the sample and record the chromatogram. The result is as follows: Figure 4 and as shown in Table 8.

[0125] Table 8 HPLC results

[0126]

[0127]

[0128] The specificity of the method was investigated using samples of this product degraded under strong light. The results showed that the retention time was 33.337 minutes, and the impurity peak was not completely separated from the adjacent impurity peaks, requiring further optimization.

[0129] Comparative Example 4

[0130] 1. The instruments and reagents are the same as those in Example 1.

[0131] 2. Liquid chromatography conditions

[0132] Detector: UV detector;

[0133] Chromatographic column: chromatographic column with octadecylsilane bonded silica as filler (Ultimate XB-C18 150mm×4.6mm, 3μm or chromatographic column with equivalent separation performance);

[0134] Mobile phase: Mobile phase A: pH 3.5 phosphate buffer-acetonitrile-water (2:20:78); Mobile phase B: acetonitrile;

[0135] The gradient elution program is shown in Table 9:

[0136] Table 9

[0137] Time (minutes) Mobile phase A (%) Mobile phase B (%) 0 75 25 5 75 25 20 70 30 40 10 90 45 10 90 46 75 25 55 75 25

[0138] Flow rate: 1.0 mL / min;

[0139] Column temperature: 30°C;

[0140] Detection wavelength: 233nm;

[0141] Injection volume: 20 μL.

[0142] 3. Take one vial of dexketoprofen tromethamine injection and place it in a light box (5500Lux±500Lux) for 3 hours. Take it out and accurately measure 2mL and place it in a 50mL volumetric bottle. Dilute it to the mark with diluent and shake well to obtain the light-damaged test solution. Inject the sample and record the chromatogram. The result is as follows: Figure 5 and as shown in Table 10.

[0143] Table 10 HPLC results

[0144]

[0145] The specificity of the method was investigated by using samples of this product degraded by strong light. The results showed that the separation between the main peak and the adjacent impurity peaks and each impurity peak before the retention time of 25 minutes was greater than 1.5, and the minimum separation between the impurity peaks after 25 minutes was 1.3, which basically met the requirements for the inspection of related substances, but the separation effect was not as good as that in Example 1.

[0146] Taking into account the peak shape of the main peak of the test sample and to avoid overloading, the injection volume was adjusted to 15 μL, and the light-destroyed sample solution was injected for inspection according to gradient elution. The results showed that when the injection volume was 15 μL and 20 μL, the impurity detection capabilities of each destroyed sample were basically the same. In subsequent experiments, the injection volume was adjusted to 15 μL.

[0147] Since the buffer salt and the aqueous phase are measured separately during the preparation of mobile phase A, and the amount of buffer salt is small, it is easy to cause volume measurement errors. In subsequent experiments, the buffer salt and the aqueous phase are planned to be combined, that is, pH 3.5 phosphate buffer-acetonitrile (80:20), in which the buffer salt concentration is converted to 0.015 mol / L to optimize the preparation of the phosphate solution and simplify the operation.

[0148] Considering that mobile phase A may salt out when mixed with a high proportion of organic phase, reducing the proportion of mobile phase B was considered.

[0149] Methodological validation

[0150] 1. Specificity test

[0151] Dexketoprofen tromethamine reference substance and each impurity reference substance were measured according to the optimal determination method screened in Example 1 above. The system suitability test results are shown in Figure 6 , Table 11 and Table 12, in the system suitability chromatograms, impurity C, impurity P, impurity E, impurity B, impurity O, dexketoprofen, impurity A, impurity D, impurity F, impurity Q, impurity M and impurity N appear in sequence, and the separation between each chromatographic peak is greater than 1.5, and the separation is good.

[0152] Take 15 μL of blank auxiliary material solution, inject it into liquid chromatograph, record the chromatogram, and the results are shown in Figure 7 The peaks of blank auxiliary materials and blank solvents both appeared 2 minutes earlier, and there was no interference with the detection of impurities of related substances. Take 15 μL of the sensitivity solution, inject it into the liquid chromatograph, record the chromatogram, and the results are shown in Figure 8 , the signal-to-noise ratio of the main component peak of the sensitivity solution is 105.1, which is greater than 10. The method has good specificity.

[0153] Table 11 HPLC results

[0154]

[0155]

[0156] Table 12 Results of system suitability test of related substances of dexketoprofen tromethamine injection

[0157]

[0158] 2. Accuracy test

[0159] The accuracy of the method was achieved by examining the accuracy solution of different amounts of impurity reference stock solution added to the blank excipient. The concentrations of each impurity examined included 25% of the limit concentration, 100% of the limit concentration, and 150% of the limit concentration. Three copies of each concentration were prepared in parallel, and the mean recovery rate and relative standard deviation met the requirements. The method has good accuracy, and the results are shown in Table 12.

[0160] Table 12 Results of accuracy tests for various impurities

[0161]

[0162]

[0163] 3. Precision test

[0164] The precision test was conducted by repeatability and intermediate precision. Repeatability was tested by preparing 6 portions of 100% spiked test solution in parallel, and the recovery and relative standard deviation were calculated by the main component external standard method and impurity external standard method with correction factors. The difference between the results of the two methods was calculated. Intermediate precision was verified by repeatability by different personnel, dates, and instruments; and the relative standard deviation of the 12 results was calculated. The results are shown in Tables 13, 14, and 15.

[0165] The difference in the content of each known impurity of this product calculated by the impurity external standard method and the main component external standard method with correction factor is less than 0.04%, that is, there is no significant difference in the related substances of this product calculated by the impurity external standard method and the main component external standard method with correction factor. This method has good precision.

[0166] Table 13 Calculation results of precision impurities by external standard method

[0167]

[0168]

[0169] Table 14 Calculation results of precision plus correction factor principal component external standard method

[0170]

[0171]

[0172] Table 15 Summary of the results of the precision impurity external standard method and the principal component external standard method with correction factor

[0173]

[0174] 4. Detection limit and quantification limit test

[0175] Take appropriate amount of dexketoprofen trometamol and each impurity reference substance, dissolve in diluent and gradually dilute, shake well, accurately measure 15 μL and inject into liquid chromatograph until the signal-to-noise ratio of each component peak is 10 and 3, which are the quantitative limit and detection limit of the corresponding component, and the quantitative limit solution is injected six times continuously, and the relative standard deviation of the peak area is not more than 10.0%. The results are shown in Table 16.

[0176] Table 16 Detection limit and quantification limit test results

[0177]

[0178]

[0179] 5. Linearity test

[0180] The linearity of the method was achieved by examining the linearity of at least six solutions with different concentrations, including the quantitative limit concentration. The measured peak area was plotted against the concentration, and the regression equation, correlation coefficient and intercept were calculated using the least squares method. The method had good linearity, as shown in Table 17. Fig. 9 .

[0181] Table 17 Linearity test results

[0182]

[0183]

[0184] 6. Durability test

[0185] The durability of the method was investigated by changing the chromatographic column batch, column temperature, detection wavelength, flow rate, and mobile phase pH value. Compared with the standard conditions, the system suitability test met the standard requirements under each variable chromatographic parameter, and the number of impurities in the chromatogram of the test solution was consistent (content greater than 0.05%), the impurity content was 0.05% to 0.5%, and the RSD value was less than 10.0%; the impurity content was 0.5% to 2%, and the RSD value was less than 5.0%. It met the acceptance criteria, indicating that the method has good durability by fine-tuning the chromatographic parameters such as detection wavelength, flow rate, column temperature, mobile phase pH value, and using different chromatographic column batches. The results are shown in Tables 18 and 19.

[0186] Table 18 System suitability results of various variable parameters

[0187]

[0188]

[0189] Table 19 Results of test solution for each variable parameter

[0190]

[0191]

[0192] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.

Claims

1. A high performance liquid chromatography analysis method for impurities in dexketoprofen tromethamine, characterized in that, The following steps are involved: Take the dexketoprofen tromethamine sample to be tested, prepare a test solution, inject the test solution into a high performance liquid chromatograph, and detect and record the chromatogram under the following chromatographic conditions; use octadecylsilane bonded silica gel as a filler; use phosphate-acetonitrile solution as mobile phase A; use acetonitrile as mobile phase B; the elution method is gradient elution; the procedure of the gradient elution is: 。 2. The high performance liquid chromatography analysis method of dexketoprofen trometamol related substances according to claim 1, characterized in that, The impurities of the dexketoprofen tromethamine include the following substances:

3. The high performance liquid chromatography analysis method of dexketoprofen trometamol related substances according to claim 2, characterized in that, The steps include: 1) Preparation of test solution: Take the dexketoprofen tromethamine sample to be tested and dissolve it in the diluent to prepare the test solution; Preparation of control solution: Take the test solution and further dilute it with diluent to obtain the control solution; Preparation of system suitability solution: take appropriate amount of impurity A reference substance, impurity B reference substance, impurity C reference substance, impurity D reference substance, impurity E reference substance, impurity F reference substance, impurity M reference substance, impurity N reference substance, impurity O reference substance, impurity P reference substance, impurity Q reference substance and dexketoprofen tromethamine reference substance, and prepare system suitability solution with diluent; 2) Use high performance liquid chromatography to measure the system suitability solution, control solution and test solution respectively, inject them into the chromatograph, perform gradient elution, and record the chromatogram.

4. The high performance liquid chromatography analysis method of dexketoprofen tromethamine related substances according to claim 3, characterized in that, The diluent is prepared by mixing 1wt% phosphoric acid solution with acetonitrile. In the diluent, the volume percentage of the 1wt% phosphoric acid solution is 40-60%.

5. The high performance liquid chromatography analysis method of dexketoprofen trometamol related substances according to claim 1, characterized in that, The chromatographic conditions also include: a column temperature of 25 to 35° C.; and a flow rate of 0.9 to 1.1 mL / min.

6. The high performance liquid chromatography analysis method of dexketoprofen tromethamine related substances according to claim 1, characterized in that, The chromatographic conditions also include: the detector is an ultraviolet detector; and the detection wavelength is 231-235 nm.

7. The high performance liquid chromatography analysis method of dexketoprofen tromethamine related substances according to claim 1, characterized in that, The mobile phase A is prepared by configuring a phosphate solution and acetonitrile, and the pH value of the phosphate solution is 3.4-3.

6.

8. The high performance liquid chromatography analysis method of dexketoprofen trometamol related substances according to claim 7, characterized in that, The volume ratio of the phosphate solution to acetonitrile is 4:

1.

9. The high performance liquid chromatography analysis method of dexketoprofen tromethamine related substances according to claim 1, characterized in that, The chromatographic conditions used a chromatographic column with a filler particle size of 3 μm.

10. The high performance liquid chromatography analysis method for the related substances of dexketoprofen tromethamine according to claim 1, characterized in that: The method comprises the following steps: firstly, the dexketoprofen tromethamine sample to be tested is subjected to light destruction.

Citation Information

Patent Citations

  • Group of novel dexketoprofen trometamol impurities, and preparation method thereof

    CN113461561A

  • Dexketoprofen trometamol injection and preparation method thereof

    CN118370720A

  • Process for preparing a stable pharmaceutical composition comprising dexketoprofen trometamol

    EP2764875A1

Cited By

  • Method for quantitatively detecting dexketoprofen trometamol injection and related substance levoketoprofen of dexketoprofen trometamol injection by high performance liquid chromatography

    CN119985801A